Continuous flow pumps and total artificial hearts: management issues.
Feasibility studies are underway for new axial flow ventricular assist systems and with a total artificial heart (TAH). The axial flow pumps provide continuous flow from the left ventricle (LV) to the aorta; the TAH provides pulsatile flow to the pulmonary and systemic circulation. Understanding the differences between these systems is necessary for appropriate patient selection and management. We compared the Jarvik 2000 axial-flow pump and the AbioCor TAH. The Jarvik 2000 pump is placed in the LV with its outflow graft anastomosed to the aorta. This system is used for bridge-to-transplantation and destination therapy. The AbioCor TAH provides complete circulatory support. The AbioCor is used for destination therapy in patients expected to die in less than 30 days. Worldwide, 45 patients have received the Jarvik 2000 as a bridge to transplantation (n = 34) or destination therapy (n = 11) for an average duration of support of 132.8 days (5 to 853 days). In 30 bridge-to-transplantation cases, 14 patients (47%) have undergone heart transplantation, 5 (17%) continue to be supported with the Jarvik 2000 device, and 11 (37%) have died. Five of 7 patients supported by the AbioCor TAH survived beyond the perioperative period; 4 were ambulatory, 2 were discharged from the hospital, and 1 is at home 13 months after implantation. Anticoagulation therapy and infection management are necessary for both systems. Therapy with inotropic agents, vasoactive drugs, a pacemaker, and electrolyte normalization is necessary for Jarvik patients. AbioCor-supported patients do not require medications to support heart function. Vasoactive agents may be useful for controlling blood pressure.